DiaGenic has teamed up with GE Healthcare to develop a blood-based test using DiaGenic's peripheral gene expression profiling in patients with mild cognitive impairment, a disorder associated with risk for Alzheimer's Disease.
The research will combine expertise in data integration, informatics, genomics and imaging to identify subjects at risk of Alzheimer's at an early disease stage.
The study will be used in conjunction with PET imaging to identify a blood based gene expression signature in these patients.
GE Healthcare Medical Diagnostics MI PET segment general manager Jonathan Allis said the company is committed to providing innovations that may accelerate diagnosis of neurodegenerative diseases such as Alzheimer's disease and transform patient management.
"Finding a signature that identifies people at risk of developing the disease, may enable physicians to make more informed decisions about patient care," Allis added.
DiaGenic CEO Erik Christensen said: "Combining PET and gene expression data will be very valuable for DiaGenic and a biomarker linked to PET will open new market opportunities for DiaGenic and GE Healthcare."
